Virtus Advisers LLC Takes Position in Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Virtus Advisers LLC has established a new position in Amneal Pharmaceuticals by acquiring 35,921 shares valued at approximately $301,000.
• Several institutional investors have increased their holdings in Amneal, with notable increases from Nuveen LLC and Walleye Capital LLC, among others.
• Analysts have a consensus rating of "Buy" for Amneal Pharmaceuticals, with a price target averaging around $11.60, despite a recent downgrade from a "strong-buy" rating by Wall Street Zen.

Virtus Advisers LLC bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 35,921 shares of the company's stock, valued at approximately $301,000.

A number of other institutional investors also recently modified their holdings of AMRX. Nuveen LLC acquired a new position in shares of Amneal Pharmaceuticals during the first quarter worth approximately $19,581,000. Nantahala Capital Management LLC grew its holdings in Amneal Pharmaceuticals by 37.3% during the fourth quarter. Nantahala Capital Management LLC now owns 3,665,529 shares of the company's stock worth $29,031,000 after buying an additional 995,586 shares in the last quarter. Vanguard Group Inc. grew its holdings in Amneal Pharmaceuticals by 6.2% during the first quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company's stock worth $132,092,000 after buying an additional 920,758 shares in the last quarter. Walleye Capital LLC grew its holdings in Amneal Pharmaceuticals by 1,333.7% during the first quarter. Walleye Capital LLC now owns 558,842 shares of the company's stock worth $4,683,000 after buying an additional 519,863 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in Amneal Pharmaceuticals by 218.8% during the fourth quarter. Bank of America Corp DE now owns 556,881 shares of the company's stock worth $4,410,000 after buying an additional 382,222 shares in the last quarter. 31.82% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on AMRX. Wall Street Zen downgraded Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th. The Goldman Sachs Group began coverage on Amneal Pharmaceuticals in a report on Friday, June 6th. They set a "buy" rating and a $12.00 price target for the company. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $11.60.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ:AMRX opened at $9.59 on Monday. The company has a market capitalization of $3.01 billion, a PE ratio of 959.96 and a beta of 1.11. The business has a fifty day moving average price of $8.38 and a two-hundred day moving average price of $8.01. Amneal Pharmaceuticals, Inc. has a 1 year low of $6.68 and a 1 year high of $9.79.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. Sell-side analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, EVP Nikita Shah sold 71,694 shares of the stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $9.29, for a total transaction of $666,037.26. Following the completion of the transaction, the executive vice president owned 267,235 shares in the company, valued at approximately $2,482,613.15. This represents a 21.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jason B. Daly sold 22,000 shares of the stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total value of $199,100.00. Following the transaction, the executive vice president owned 10,606 shares of the company's stock, valued at $95,984.30. The trade was a 67.47% decrease in their position. The disclosure for this sale can be found here. Insiders sold 456,374 shares of company stock worth $4,239,042 in the last quarter. 26.56% of the stock is currently owned by company insiders.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.